Plain-English translation of NCT06745687 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This study is testing a new medication called CM-336, which is a bispecific antibody designed to fight multiple myeloma. Researchers want to see if giving this medication early—before the disease fully develops—can stop it from progressing and help patients avoid serious complications. The medication has shown promising results in patients with more advanced myeloma, and doctors hope it may work well in this earlier stage too.
Smoldering multiple myeloma is a condition where cancer cells are growing but haven't yet caused severe organ damage. Right now, doctors don't have a standard treatment plan for this stage, and it often progresses to full multiple myeloma. Early treatment with this medication might prevent that progression and improve your long-term health.
You likely qualify if…
You likely don't qualify if…
You would receive CM-336 as a subcutaneous injection (a shot under the skin). The trial will track your safety and how well the medication works by monitoring your blood tests and imaging over time. This is a relatively small study enrolling about 20 people in China, and your doctors will carefully watch for any side effects while evaluating whether the medication helps control your myeloma.
AI-generated summary from trial data · Aug 2, 2026 · Not medical advice
China
Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Collaborators
Keymed Biosciences Co.Ltd
Enrollment target
~20 participants
Started
December 2024
Primary completion
August 2027
Age range
18 Years – 78 Years
Last updated on clinicaltrials.gov in July 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Gang An, MD, PhD
Institute of Hematology & Blood Diseases Hospital, China
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.